Research & Education
CURE Expert Connections
Email Sign Up
To start your customized experience click the start button
Customize your homepage by selecting specific cancer types.
Cancer of Unknown Primary
Diet and Exercise
Gastrointestinal stromal tumor
General Financial Topics
General Psychosocial Aspect Topics
Head & Neck Cancer
Mantle Cell Lymphoma
Metastatic Breast Cancer
Side Effect Management
Small Lymphocytic Lymphoma (SLL)
Advocacy & Research
Share Your Story
Newsletter Sign Up
Ovarian Cancer Heroes
Bone Health Champions
Terms & Conditions
Cure Media Group, LLC.
2 Clarke Drive
Cranbury, NJ 08512
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Immunotherapy Pair Good for Some, Not All, With Kidney Cancer
Sumanta K. Pal, M.D.
Yervoy plus Opdivo is a good combination for many patients with kidney cancer, though some individuals should steer clear of the regimen.
Obesity Factors May Increase Kidney Cancer Risk
Certain factors – such as diastolic blood pressure and fasting insulin – were found to be associated with renal cell carcinoma.
Occupational Gasoline Exposure May Increase Kidney Cancer Risk
People who have experienced high exposures to gasoline might be at an increased risk for kidney cancer, according to recent research.
Staying Vigilant to Manage Treatment-Related Side Effects in Kidney Cancer
Treatment side effects are typically manageable for patients with metastatic kidney cancer, but patients must have open communication with their health care team about them.
Contrary to Previous Studies, Sex May Not Impact Efficacy of Immunotherapy
A recent meta-analysis has found no noticeable difference in immunotherapy’s efficacy based on patient sex.
Fotivda Lengthens Time to Disease Progression in Renal Cell Carcinoma
Kristie L. Kahl
The phase 3 TIVO-3 trial – designed to evaluate the efficacy of Fotivda in patients with renal cell carcinoma – met its primary endpoint of improved progression-free survival.
CURE New Issue Alert: Fall 2018
Katie Kosko and Jessica Skarzynski
We've got a sneak peek at what’s inside our Fall 2018 issue.
Immunotherapy Is 'Here to Stay' in Kidney Cancer
Checkpoint inhibitors are moving into the treatment realm of renal cell carcinoma; however, questions still remain.
Distress Levels High Among Patients With Common Form of Kidney Cancer
Many patients with renal cell carcinoma, the most common type of kidney cancer, experience high levels of distress, according to study findings published in
A State of Flux for Kidney Cancer
DEBORAH ABRAMS KAPLAN
Targeted drugs are controversial in early-stage kidney cancer, but play a more important role in treating advanced disease.
Not a member?
Sign up now!
Continue without login
OPTIONAL INFORMATION: The following information helps us tailor CURE to fit your needs
Please type below what best describes your interests and click on the selection(s):
I am a:
Please list other: